ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

AbbVie, Aclaris Therapeutics and Bayer side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

AbbVie×Aclaris Therapeutics×Bayer×Three at a time for now; Pro will compare up to ten.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

AbbVieAclaris TherapeuticsBayer
studies on the registry2,251341,694
open to participants now133160
phase 3 studies under way74011
reach primary completion within a year90035
programswith a study of their own in two years70+8 named only221

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseAbbVieAclaris TherapeuticsBayer
Phase 1

AbbVie: 28 of its 70 programs at phase 1

  1. Anti-CD19-Glucosteroid Receptor Modulator ADC ABBV-31phase 1
  2. surzetoclaxphase 1
  3. BTK Degrader ABBV-101phase 1
  4. ABBV-1162phase 1
  5. ABBV-1451phase 1

and 23 more — sign in to see them all

40%
00%19%
Phase 2

AbbVie: 20 of its 70 programs at phase 2

  1. ABBV-295phase 2
  2. zumilokibartphase 2
  3. ABBV-932phase 2
  4. trosunilimabphase 2
  5. ABBV-701phase 2

and 15 more — sign in to see them all

29%

Aclaris Therapeutics: 2 of its 2 programs at phase 2

  1. modzatinibphase 2
  2. ATI-045phase 2
100%

Bayer: 8 of its 21 programs at phase 2

  1. AB-1005phase 2
  2. WRN Inhibitor RO7589831phase 2
  3. nurandociguatphase 2
  4. BAY 3401016phase 2
  5. BAY 3670549phase 2

and 3 more — sign in to see them all

38%
Phase 3

AbbVie: 16 of its 70 programs at phase 3

  1. telisotuzumab adizutecanphase 3
  2. etentamigphase 3
  3. lutikizumabphase 3
  4. mirvetuximab soravtansinephase 3
  5. turmetabart adizutecanphase 3

and 11 more — sign in to see them all

23%
00%

Bayer: 4 of its 21 programs at phase 3

  1. elinzanetantphase 3
  2. sevabertinibphase 3
  3. bemdaneprocelphase 3
  4. aficamtenphase 3
19%
Approved, new studies

AbbVie: 6 of its 70 programs at approved, new studies

  1. upadacitinibapproved, new study
  2. risankizumabapproved, new study
  3. venetoclaxapproved, new study
  4. botulinum toxin type Aapproved, new study
  5. atogepantapproved, new study

and 1 more — sign in to see them all

9%
00%

Bayer: 5 of its 21 programs at approved, new studies

  1. finerenoneapproved, new study
  2. darolutamideapproved, new study
  3. Aspirinapproved, new study
  4. acoramidisapproved, new study
  5. Levonorgestrelapproved, new study
24%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
AbbVie34 readouts · 5 phase 3

AbbVie, Nov ’26: 6 programs whose next study reaches primary completion, 1 in phase 3

  1. ABBV-701phase 2 · Nov 0 · NCT06895343
  2. ABBV-932phase 2 · Nov 0 · NCT06846320
  3. mirvetuximab soravtansinephase 3 · Nov 0 · NCT05456685
  4. upadacitinibapproved, new study · Nov 0 · NCT06389136
  5. venetoclaxapproved, new study · Nov 0 · NCT04895436

and 1 more — sign in to see them all

AbbVie, Dec ’26: 4 programs whose next study reaches primary completion, 1 in phase 3

  1. ABBV-295phase 2 · Dec 0 · NCT07514260
  2. emraclidinephase 2 · Dec 0 · NCT07219030
  3. lutikizumabphase 3 · Dec 0 · NCT06468228
  4. telisotuzumab adizutecanphase 3 · Dec 0 · NCT06107413

AbbVie, Jan ’27: 1 program whose next study reaches primary completion

  1. risankizumabapproved, new study · Jan 0 · NCT07466550

AbbVie, Feb ’27: 9 programs whose next study reaches primary completion

  1. [11C]ABBV-112iearly phase 1 · Feb 0 · NCT07933497
  2. ABBV-859phase 1 · Feb 0 · NCT07736638
  3. Anti-CD19-Glucosteroid Receptor Modulator ADC ABBV-31phase 1 · Feb 0 · NCT05512390
  4. etentamigphase 3 · Feb 0 · NCT06223516
  5. MEDI0618phase 2 · Feb 0 · NCT06602479

and 4 more — sign in to see them all

·

AbbVie, Apr ’27: 1 program whose next study reaches primary completion

  1. ABBV-1451phase 1 · Apr 0 · NCT07570147

AbbVie, May ’27: 6 programs whose next study reaches primary completion, 1 in phase 3

  1. ABBV-1162phase 1 · May 0 · NCT07832708
  2. ABBV-243phase 1 · May 0 · NCT07306754
  3. ABBV-7828phase 1 · May 0 · NCT07856706
  4. Anti-PSMA/STEAP1 Antibody-drug Conjugate ABBV-969phase 1 · May 0 · NCT06318273
  5. trosunilimabphase 2 · May 0 · NCT07925983

and 1 more — sign in to see them all

AbbVie, Jun ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. botulinum toxin type Aapproved, new study · Jun 0 · NCT07794891

AbbVie, Jul ’27: 4 programs whose next study reaches primary completion

  1. ABBV-1606phase 1 · Jul 0 · NCT07935564
  2. azirkitugphase 1 · Jul 0 · NCT05005403
  3. surzetoclaxphase 2 · Jul 0 · NCT06291220
  4. surzetoclaxphase 1 · Jul 0 · NCT06291220

AbbVie, Aug ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. vedolizumabphase 3 · Aug 0 · NCT06880744

AbbVie, Sep ’27: 1 program whose next study reaches primary completion

  1. icalcaprantphase 2 · Sep 0 · NCT07276997
·
Aclaris Therapeutics0 readouts · 0 phase 3············
Bayer10 readouts · 4 phase 3·

Bayer, Dec ’26: 1 program whose next study reaches primary completion

  1. BAY 3389934phase 1 · Dec 25 · NCT06854640

Bayer, Jan ’27: 1 program whose next study reaches primary completion

  1. elinzanetantphase 3 · Jan 22 · NCT07762287
·

Bayer, Mar ’27: 1 program whose next study reaches primary completion

  1. Aspirinapproved, new study · Mar 10 · NCT07652723

Bayer, Apr ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. finerenoneapproved, new study · Apr 10 · NCT05196035

Bayer, May ’27: 2 programs whose next study reaches primary completion

  1. nurandociguatphase 2 · May 7 · NCT07431294
  2. WRN Inhibitor RO7589831phase 2 · May 31 · NCT06004245
·

Bayer, Jul ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. darolutamideapproved, new study · Jul 30 · NCT05794906

Bayer, Aug ’27: 1 program whose next study reaches primary completion

  1. RAS/PI3K-alpha Inhibitor VVD-159642phase 1 · Aug 1 · NCT06804824

Bayer, Sep ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. acoramidisapproved, new study · Sep 17 · NCT07298044

Bayer, Oct ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. sevabertinibphase 3 · Oct 28 · NCT06452277
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 21, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

AbbVie

New programs 5

Reached a new phase 1

  • ABBV-722phase 3 · Oct 23 · Scleroderma, Systemic

Study stopped 0

None

Primary completion later 10

Aclaris Therapeutics

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Bayer

New programs 0

None

Reached a new phase 1

Study stopped 0

None

Primary completion later 2

Where they overlap

Conditions where at least two of them have programs: 9 in all. A program counts in each condition its studies name most.

ConditionAbbVieAclaris TherapeuticsBayer
Carcinoma, Non-Small-Cell Lung2 of 3 · compare here

AbbVie in Carcinoma, Non-Small-Cell Lung: 4 programs

  1. telisotuzumab adizutecanphase 3
  2. ABBV-1480phase 3
  3. azirkitugphase 1
  4. RC148no phase

Their studies: AbbVie’s studies of Carcinoma, Non-Small-Cell Lung in search

–

Bayer in Carcinoma, Non-Small-Cell Lung: 2 programs

  1. sevabertinibphase 3
  2. PRMT5 Inhibitor BAY 3713372phase 2

Their studies: Bayer’s studies of Carcinoma, Non-Small-Cell Lung in search

Dermatitis, Atopic2 of 3 · compare here

AbbVie in Dermatitis, Atopic: 3 programs

  1. zumilokibartphase 2
  2. APG990phase 1
  3. upadacitinibapproved, new study

Their studies: AbbVie’s studies of Dermatitis, Atopic in search

Aclaris Therapeutics in Dermatitis, Atopic: 2 programs

  1. modzatinibphase 2
  2. ATI-045phase 2

Their studies: Aclaris Therapeutics’ studies of Dermatitis, Atopic in search

–
Colorectal Neoplasms2 of 3 · compare here

AbbVie in Colorectal Neoplasms: 3 programs

  1. telisotuzumab adizutecanphase 3
  2. trifluridine tipiracil drug combinationphase 3
  3. RC148no phase

Their studies: AbbVie’s studies of Colorectal Neoplasms in search

–

Bayer in Colorectal Neoplasms: 1 program

  1. WRN Inhibitor RO7589831phase 2

Their studies: Bayer’s studies of Colorectal Neoplasms in search

Neoplasms2 of 3 · compare here–

Bayer in Neoplasms: 1 program

  1. darolutamideapproved, new study

Their studies: Bayer’s studies of Neoplasms in search

Parkinson Disease2 of 3 · compare here

AbbVie in Parkinson Disease: 1 program

  1. tavapadonphase 3

Their studies: AbbVie’s studies of Parkinson Disease in search

–

Bayer in Parkinson Disease: 2 programs

  1. bemdaneprocelphase 3
  2. AB-1005phase 2

Their studies: Bayer’s studies of Parkinson Disease in search

Amyloidosis2 of 3 · compare here

AbbVie in Amyloidosis: 1 program

  1. etentamigphase 3

Their studies: AbbVie’s studies of Amyloidosis in search

–

Bayer in Amyloidosis: 1 program

  1. acoramidisapproved, new study

Their studies: Bayer’s studies of Amyloidosis in search

Carcinoma, Hepatocellular2 of 3 · compare here

AbbVie in Carcinoma, Hepatocellular: 1 program

  1. telisotuzumab adizutecanphase 3

Their studies: AbbVie’s studies of Carcinoma, Hepatocellular in search

–
Prostatic Neoplasms2 of 3 · compare here–

Bayer in Prostatic Neoplasms: 1 program

  1. darolutamideapproved, new study

Their studies: Bayer’s studies of Prostatic Neoplasms in search

Schizophrenia2 of 3 · compare here

AbbVie in Schizophrenia: 1 program

  1. emraclidinephase 2

Their studies: AbbVie’s studies of Schizophrenia in search

–

Bayer in Schizophrenia: 1 program

  1. elinzanetantphase 3

Their studies: Bayer’s studies of Schizophrenia in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

A target, or a pathogen for a vaccine, known for: AbbVie 54 of 70 · Aclaris Therapeutics 0 of 2 · Bayer 13 of 21 programs (26 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (AbbVie: 8).